• INJECT CAPITAL
  • JOIN
    • Incubator
    • HealthTech Bootcamp
    • BioTech Bootcamp
    • FoodTech Bootcamp
    • e-Campus
    • e-Dragon Academy
    • Open Lab South
  • STAY
    • Incubation process
    • Labs & equipment
    • SDG Scan
    • Offices & Services
    • CEO group
    • Extra Benefits
  • SCALE
    • Alumni membership
    • Success stories
  • COLLABORATE
    • Member startups
    • Member alumni
    • Alumni
    • Industry network
    • Investor network
    • Sponsors
    • Founding partners
    • Dragon Academy
    • Servier Golden Ticket
    • Abbvie Golden Ticket
    • Projects
  • NEWS
    • News
    • Sign up for newsletter
    • Sign up for investors newsletter
  • EVENTS
  • SMILE
    • About SmiLe
    • Team & board
    • About the region
  • CONTACT US
  • Search
  • Menu Menu
Sign up for the SmiLe newsletter

Latest News

2025-12-22 08:15Press release

First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

Xinnate has publiched its first-in-human, open-label, single-arm clinical study evaluating the safety, tolerability, and systemic exposure of topically applied TCP-25, the company’s novel immunomodulatory peptide, in patients with Epidermolysis Bullosa (EB).

2025-12-16 08:20Press release

Xinnate Completes Oversubscribed Share Issue of €3.6 million

Xinnate AB today has completed of an oversubscribed share issue of €3.6 million from existing and new investors. The financing reflects continued confidence in the company’s clinical progress and long-term strategy, including the recently communicated FDA IND approval for a clinical phase 2/3 study.

2025-12-09 09:28Press release

Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa

Xinnate is taking a major step toward reshaping the treatment landscape for Epidermolysis Bullosa with the FDA’s approval of its IND application for TCP-25 – positioning the company’s lead asset for a pivotal Phase 2/3 program and creating a clear path toward U.S. market entry.

2025-12-03 09:12Press release

SmiLe Venture Hub receives two awards from the International Chamber of Commerce and Mind the Bridge

SmiLe Venture Hub has been named one of the winners of the Startup Ecosystem Stars 2025 Awards in two categories: Best-in-class Startup Programs and Outstanding Investment Boost. The awards are presented by the International Chamber of Commerce (ICC) and Mind the Bridge.

2025-12-03 09:00Press release

SmiLe Venture Hub får två utmärkelser av International Chamber of Commerce och Mind the Bridge

SmiLe Venture Hub har utsetts till en av vinnarna av Startup Ecosystem Stars 2025 Awards i två kategorier: Best-in-class Startup Programs och Outstanding Investment Boost. Utmärkelserna delas ut av International Chamber of Commerce (ICC) och Mind the Bridge.

2025-12-03 08:58Press release

SmiLe Venture Hub receives two awards from the International Chamber of Commerce and Mind the Bridge

SmiLe Venture Hub has been named one of the winners of the Startup Ecosystem Stars 2025 Awards in two categories: Best-in-class Startup Programs and Outstanding Investment Boost. The awards are presented by the International Chamber of Commerce (ICC) and Mind the Bridge.

2025-12-02 10:53Press release

Cirkulär awarded € 226 000 to upcycle forest-based industry waste streams into multiple high-value products

After launching its first product this autumn – becoming the first in the world to commercialize mycoprotein for aquaculture – Cirkulär has now been awarded € 226 000 from FORMAS to investigate how additional high-value substances can be obtained through the same process.

2025-10-22 15:12Press release

Cytely AB raises capital to accelerate discoveries that can cure diseases

Cytely has raised €3 million in a funding round led by Danish Ugly Duckling Ventures. The new capital will be used to support international expansion of the company’s AI-driven microscopy platform, which automates cell analysis and accelerates biomedical research.

2025-10-06 08:30Press release

Promising results for Lead Biologics’ first-in-class checkpoint inhibitor published in Nature Cancer

Lead Biologics, a company in SmiLe's incubator program, takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced experimental models.

2025-06-18 11:48Press release

A Successful Year of Collaboration: AbbVie Golden Ticket Comes to a Close

The one-year AbbVie Golden Ticket program has officially concluded – marking the end of a highly successful collaboration between AbbVie, SmiLe Venture Hub, and AAX Biotech, the winning startup of 2024.

2025-06-10 11:20News

Reccan Joins EU-Led SHIELD Project to Revolutionize Early Pancreatic Cancer Detection

Reccan AB has a pivotal role in the launch of SHIELD, a €14 million, Horizon Europe-funded project dedicated to transforming the early detection of pancreatic cancer across Europe. 26 partners from 13 countries are focused on improving survival rates through proactive diagnostics in high-risk individuals.

2025-05-20 08:30Press release

Xinnate announces successful FDA meeting for TCP-25

Xinnate AB, a clinical-stage company focused on developing treatments for patients with Epidermolysis Bullosa (EB), today announced that positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA): the upcoming study is now being upgraded to serve as a registrational trial.

2025-05-16 09:47Press release

MedVasc raises SEK 10 Million to accelerate final development and FDA preparation for Solutio™ device

MedVasc AB has successfully closed a SEK 10 million financing round. The funding supports the company’s final product development phase and preparation for FDA regulatory approval in the United States.

2025-05-06 08:20Press release

RECCAN AB Secures SEK 7 Million Investment to Advance Groundbreaking Pancreatic Cancer Test Towards Market

RECCAN AB has secured SEK 7 million through a directed share issue, with Sandberg Development as the lead investor. The capital will fund clinical validation and verification of production processes ahead of CE marking and a European launch.

2025-04-16 14:56News

Open Call for Applications to Support Cellular Agriculture Innovators Entering the EU Market

APROVALS (Accelerating PROteins innoVAtion beyond reguLatory Sandboxes), a EU-funded initiative, is dedicated to advancing regulatory innovation in cellular agriculture, particularly cell-grown meat. We invite companies aiming to enter the European market to apply from April 14 to June 9, 2025.

2025-04-14 12:05Press release

SmiLe Strengthens Global Life Science Innovation by Supporting the Launch of Finnish OYSTER Incubator

SmiLe Venture Hub is supporting the development and launch of the new OYSTER Incubator, designed to accelerate health and life science innovation in Finland.

2025-04-07 15:29News

Apply for the Servier Golden Ticket 2025 – a unique opportunity to accelerate your research and development efforts

Applications are now open for the Servier Golden Ticket – a program sponsored by Servier in collaboration with SmiLe Venture Hub, designed to support promising startup in oncology and neuroscience, developing groundbreaking therapeutics, platform technologies or AI/ML data-driven platforms for drug discovery.

2025-03-31 11:50Press release

Capillon Analytics Paves the Way for Early Cancer Diagnosis Through Hair Analysis 

The new SmiLe company Capillon Analytics is developing an innovative method for early cancer detection based on hair analysis. Using an AI-driven technology that identifies chemical signatures in hair strands, their method has the potential to revolutionize early detection of cancer.

2025-03-27 11:05Press release

New SmiLe company Strike Pharma develops next-generation precision medicine

New SmiLe company Strike Pharma has developed a technology platform that enables the selective delivery of drugs, enclosed in nanoparticles, to specific cells in the body. With this innovation, immune cells can be reprogrammed inside the body (in vivo).

2025-02-14 08:20Press release

Zeiss Becomes a New Lab Partner for SmiLe Venture Hub

SmiLe has entered into a partnership with Zeiss, a leading company in the development, manufacturing, and marketing of optical instruments. Zeiss has delivered three new microscopes and upgraded several existing ones.

2025-02-12 08:10News

SmiLe welcomes Magnhild Owman as the new People & Culture coach

SmiLe Venture Hub strengthens its support to startups by welcoming Magnhild Owman as the new People & Culture coach. With over 20 years of experience in recruitment and organizational development, she will support SmiLe's companies in leadership, corporate culture, and recruitment strategy matters.

2025-02-06 12:20Press release

New Technology from Emulsi Biotech Can Make Biological Drugs More Effective

The new SmiLe company Emulsi Biotech is developing a groundbreaking platform technology for the oral delivery of drugs. Their innovative NanoLIPID platform has the potential to protect drug substances, enable slow release, and significantly enhance the body's absorption of medications.

2025-01-29 15:09Press release

SmiLe Venture Hub takes a role in shaping the future of sustainable food through APROVALS, a significant European collaboration

We are join forces with seven prominent European agri-foodtech innovation clusters in the project to accelerate the deployment of emerging technologies in cellular agriculture

2025-01-24 10:25Press release

SmiLe Inject Capital invests 3 million SEK in Xaga Surgical

Medical technology company Xaga Surgical raises a total of 8 million SEK in an investment round, with SmiLe Inject Capital contributing 3 million SEK. Xaga Surgical develops innovative medical needles to reduce the risk of infections and improve cancer diagnostics.

2025-01-17 12:37News

SmiLe recruits Malin Sjöö to strengthen support for foodtech companies

SmiLe Venture Hub is pleased to welcome Malin Sjöö back to SmiLe as she assumes the newly established role of Chief Innovation Officer. Malin Sjöö will be responsible for further developing SmiLe’s foodtech operations and leading the work of the coaching team.

2025-01-14 08:20Press release

Xinnate receives Orphan Drug Designation from US FDA for TCP-25

Xinnate receives Orphan Drug Designation from US FDA for TCP-25, the company's drug candidate for the treatment of the severe disease Epidermolysis Bullosa (EB).

2025-01-10 08:35Press release

Bio-Rad joins SmiLe Venture Hub as new lab partner

Bio-Rad joins SmiLe Venture Hub as new lab partner. Through this partnership, Bio-Rad’s state-of-the-art QX600™ AutoDG Droplet Digital PCR System is now available to companies using SmiLe’s laboratories in Lund.

2024-12-18 08:30Press release

Dx4Life secures funding ahead of launch of its groundbreaking rapid test for IVF treatments

The SmiLe company Dx4Life has completed a new share issue, raising 6.4 million SEK to prepare for the launch of a unique rapid test that is set to significantly increase the success rate of IVF treatments.

2024-12-16 11:10News

Advancing Health Data Innovation with Data Lake

Region Skåne and SmiLe Venture Hub are collaborating on the "Data Lake" project with the long-term goal to create a secure health data repository, aimed at improving healthcare and fostering innovation.

2024-12-12 08:15Press release

Xinnate AB partners with Destum Partners, Inc. to accelerate partnership activities for TCP-25 as treatment for EB

Xinnate AB has a strategic collaboration with Destum Partners, Inc., an advisory firm specializing in the life sciences sector. Destum Partners will act as the exclusive advisor to Xinnate AB for identifying and developing partnership opportunities for TCP-25 gel, for the treatment of Epidermolysis Bullosa

2024-11-11 13:01Press release

Greenfood and Tekinn to Transform Vegetable Scraps into Nutritious Raw Material

SmiLe company Tekinn, together with Greenfood, one of the Nordic region's leading groups in healthy food, has received support from Vinnova to turn 400 tons of cabbage scraps into nutritious raw material using fermentation, with the potential to reshape the map for future food systems and their waste streams.

2024-11-04 08:15Press release

Aligned Bio secures SEK 19.4 million to scale up its groundbreaking nanowire technology

SmiLe company Aligned Bio has successfully completed a financing round, securing SEK 19.4 million to accelerate the development and scale up its nanowire production technology. The company has been accepted into the SmiLe incubator program.

2024-10-31 13:00Press release

Ulrika Ringdahl new CEO of SmiLe Venture Hub

SmiLe Deputy CEO Ulrika Ringdahl takes over as new CEO of SmiLe. She succeeds Ebba Fåhraeus who after ten years has announced that she wishes to leave the CEO role.

2024-10-21 12:30Press release

QIAGEN is New Lab Partner for SmiLe Venture Hub

QIAGEN is a new Lab Partner for SmiLe Venture Hub. Through this partnership, QIAGEN has generously equipped our laboratories with its advanced QIAcuity, a digital PCR (dPCR) instrument.

2024-04-16 08:50News

New Advisor with International Expertise Joins SmiLe's Coaching Team

SmiLe is strengthening its team with additional expertise in global business operations and entrepreneurship, and we are delighted to welcome Michael Palm as a senior advisor. 

2024-02-16 15:47News

Suturion secures 24 million for the upcoming launch

SmiLe Incubator company Suturion secures 24 million for the upcoming launch. Suturion has developed a medical instrument designed to reduce complications and enhance patient safety following open abdominal surgery.

2023-11-27 13:14News

Incubator company Manje Health signs contract to digitalize Ghana’s Medical Ecosystem

Manje Health AB has signed a contract with the government of Ghana through the national insurance company SIC Life to digitalize the country’s medical ecosystem.

2023-09-06 13:23News

The SmiLe company Yazen Health raises 37 million SEK

The SmiLe company Yazen Health raises 37 million SEK and plans to develop its digital obesity clinic and continue expanding in Europe.

2022-03-30 12:59News

SmiLe strengthens the team 

SmiLe Incubator strives to continuously improve its operations to help startup companies and entrepreneurs to commercialize their innovations. We are therefore pleased to welcome Barbara Klein and Jacob Lundgren, who will strengthen the team with their experience in project management and funding. 

2021-05-10 09:25News

JOIN US IN DRIVING BUSINESS SUCCESS THROUGH DIVERSITY

SmiLe, invites its member companies to participate in a series of workshops by the Allbright Foundation, that aim to educate and train on how to create equal and inclusive workplaces, as a means to business success.

2021-04-30 09:13News

Innovative healthtech project kickstarts at SmiLe Bootcamp

The seventh edition of SmiLe’s ten-week program for early companies and entrepreneurs with innovative ideas and products in healthtech, medtech and eHealth is now underway. The projects address key care-related areas such as pain, psychiatric disorders and postnatal problems.

2021-04-07 13:33News

Celebrating 13 SmiLe companies fighting cancer

Today we celebrate UN World Health Day by paying tribute to 13 awesome SmiLe companies fighting cancer in different ways; from early diagnosis to drug development and other advanced cancer treatment therapies.

2021-03-16 08:55News

Launch of rapid sustainability assessment for life science start-ups

Today, SmiLe announces the launch of a new rapid assessment tool – SmiLe´s SDG Scan – that makes it easy for early-stage life science businesses to measure their impact on the UN’s Sustainable Development Goals (SDGs), even if they have limited time and resources.

2021-03-08 09:22News

Join SmiLe’s charity campaign #MarchForWomen

On the occasion of International Women’s Day on March 8th, SmiLe launches, in collaboration with Skåne Stadsmission, the month-long charity ‘March for Women’ to garner support for women in need and their families.

2021-02-17 10:38News

SmiLe and the Chamber of Commerce to jointly support startup companies

SmiLe Incubator and the Chamber of Commerce and Industry have entered into a strategic partnership that provides SmiLe member companies with the benefit of accessing Chamber of Commerce and Industry member offers while the companies are at SmiLe Incubator.

2021-02-16 09:55News

Get Your Business Idea Investment‑Ready In 10 Weeks

The call for applications are officially open for the 7th batch of our SmiLe Bootcamp, formerly known as Health2B. SmiLe Bootcamp is a ten-week virtual development program designed to accelerate early-stage HealthTech, MedTech and eHealth start-ups to develop their business idea and become investment-ready.

2021-01-27 15:07News

New brand identity marks new era for SmiLe

The recent years’ transformation of SmiLe generated a need to refresh and modernize our brand visuals. Today, we are thrilled to announce the launch of our new brand identity that better reflects our expanded operations and significantly improved offering that will further benefit life science startups.

2020-12-16 10:53News

Young SmiLe entrepreneurs honored again

Young founders of SmiLe Incubator companies are honored. Alice Mattsson, has been named by Venture Cup as having one of the year’s best business ideas in southern Sweden. In addition, Maximilian Ottosson, Linn Wrangmark and Frida McCabe, along with Fábio Rosa, all qualified for the Rapidus´ "34-list".

2020-12-11 10:57News

Tomorrow’s entrepreneurs graduate from SmiLe e-Campus

The first session of SmiLe e-Campus, a training program focused on entrepreneurship in the life sciences open to participants from Europe, is coming to an end. Appreciated was SmiLe’s invaluable knowledge, and the connection to the industry through the unique collaboration with GE Healthcare and Philips Electronics.

2020-11-26 11:26News

SmiLe partners with Life Science Sweden

SmiLe is pleased to announce a new collaboration partnership with Life Science Sweden, the leading Nordic Life Science media and event organizer.

2020-11-04 15:21News

Lund-based research organisations and companies form “LundaGUARD”

“LundaGUARD” is a new consortium aimed at responding to present and future threats from infectious agents. The consortium consists of public and private organisations: SARomics Biostructures AB and Red Glead Discovery AB (two SmiLe alumni companies), LP3 at Lund University, MAX IV, ESS and UCL School of Pharmacy.

2020-10-29 15:49News

4 inspiring CEOs, 4 professional journeys

As we are wrapping up this month’s core value focus “Professional”, we would like to put the spotlight on four of our talented CEO’s. Kristina Masson, Mohamad Takwa, Hanna Sjöström and Maximilian Ottosson talk about their professional journeys, and share their top-3 tips for other young and aspiring entrepreneurs.

2020-08-28 16:47News

SmiLe – from turnaround case to recognized brand in 5 years

During the five years that Ebba Fåhraeus has been CEO of SmiLe, the life science incubator has transformed into a ‘company generator’ with strong business focus. The success factors have been a new business model for the incubator, business focus, brand, community, IR and industry expertise in the team.

2020-08-28 12:01News

Want to “SmiLe up” with us?

Hi there, Community member! The 1st of September we´re launching SmiLe Up – aka the way we live and breathe our core values. SmiLe Up is how we do things the SmiLe way. We invite you to join us as we´re about to SmiLe Up our events, our meetings and our work.

2020-07-20 14:16News

SmiLe alumni members team up against COVID-19

SmiLe alumni members Cellevate and Redoxis continue their successful collaboration, this time focusing on the development of a 3D assay for assessing drugs for the treatment of COVID-19.

2020-07-14 15:07News

Agilent’s cutting-edge 6546 LC/Q-TOF instrument now available at SmiLe’s labs

SmiLe Incubator welcomes Agilent, a global leader in laboratory instruments, as its Diamond level Lab Sponsor. Thanks to this partnership, we can now offer our startup members, Medicon Village members and other life science startups via Open Lab Skåne, access to state of the art LC/Q-TOF technology.

2020-06-10 14:38News

CEO-coaching in collaboration with SmiLe and Almi - a great success

Through a collaboration between SmiLe and Almi, eight SmiLe companies have had the opportunity to participate in a program for CEO’s, headed by Almi Företagspartner. This is the first time Almi has put together a group consisting of only life science companies and the initiative is applauded by the participants.

2020-06-05 15:21News

Power of Smile community demonstrated as Cellevate and Redoxis team up

Yet another successful collaboration in the Smile community is established: two alumni members, Redoxis and Cellevate, team up to be able to offer optimized life science services.

2020-05-25 15:11News

Bioextrax – the 15th SmiLe alumni company to launch an IPO

The 15th SmiLe alumni company, Bioextrax, has launched an IPO and is traded on Spotligth Stock Market as of April. Bioextrax specializes in research and development of technology platforms that are used to convert organic waste into various environmentally friendly materials like bioplastics, animal feed and fibres.

2020-05-17 22:03News

SmiLe strengthens team in Marketing and People & Culture

To further strengthen the SmiLe team and provide extensive support to the incubator companies, we are pleased to introduce two new team-members: Maria Sverka, Marketing Manager, and Lena Axen Jergmo, People & Culture Coach.

Svenska nyheter från SmiLe

2025-12-16 08:15Press release

Xinnate genomför övertecknad nyemission om 38,5 MSEK

Xinnate AB har genomfört en övertecknad nyemission om 38,5 MSEK. Emissionen väckte starkt intresse från både befintliga och nya investerare, vilket understryker det fortsatta förtroendet för bolagets kliniska utveckling och långsiktiga strategi inklusive det nyligen kommunicerade FDA IND-godkännandet.

2025-12-09 10:18Press release

Xinnate får FDA-godkännande av IND för TCP-25 och möjliggör registreringsgrundande fas 2/3-studie för Epidermolysis Bullosa

FDA:s godkännande av Xinnates IND-ansökan för TCP-25 markerar en viktig milstolpe i arbetet med att förbättra behandlingsmöjligheterna för Epidermolysis Bullosa och banar väg för starten av det pivotala fas 2/3-programmet STEP – ett kritiskt steg i bolagets väg mot marknadsgodkännande i USA.

2025-12-02 10:37Press release

Cirkulär får 2,5 miljoner kronor för att utvinna flera högvärdiga produkter ur restströmmar från skogsindustrin

Efter att i höst ha lanserat sin första produkt – en proteinbaserad ingrediens till fiskfoder framställd från restströmmar i skogsindustrin – har Cirkulär nu, tillsammans med Borås universitet och Kitcoat, beviljats 2,5 MSEK från FORMAS för att undersöka hur fler värdefulla substanser kan utvinnas ur samma process.

2025-10-22 14:24Press release

Cytely AB reser kapital för att påskynda upptäckter som kan bota sjukdomar

Cytely tar in 3 miljoner euro, runt 33 miljoner kronor, i en finansieringsrunda ledd av danska Ugly Duckling Ventures. Kapitalet ska användas för en internationell expansion av företagets AI-drivna mikroskopiplattform, som automatiserar cellanalyser och snabbar upp biomedicinsk forskning.

2025-10-21 15:37Press release

ImmuneBiotech stärker sin position – forskningsbaserad precisionsprobiotika lanseras på Apoteket AB

SmiLes alumnibolag ImmuneBiotech Medical Sweden AB i Lund tar nästa steg i sin tillväxtresa när den forskningsbaserade precisionsprobiotikan GutMagnific® nu finns tillgänglig via Apoteket AB:s webbshop.

2025-10-06 08:30Press release

Lovande resultat för Lead Biologics läkemedelskandidat publicerade i Nature Cancer

SmiLe-bolaget Lead Biologics tar avgörande steg mot en ny cancerbehandling. En ny studie visar att bolagets läkemedelskandidat effektivt blockerar en tidigare okänd mekanism som cancerceller använder för att undgå immunförsvaret. Detta gör att antikroppen kan eliminera cancerceller i avancerade experimentella modeller av akut myeloisk leukemi.

2025-05-20 08:10Press release

Xinnate tillkännager lyckat FDA-möte för TCP-25

Xinnate AB, som utvecklar behandlingar för patienter med Epidermolysis Bullosa (EB), har fått positiv återkoppling från sitt Type C-möte med amerikanska läkemedelsmyndigheten FDA (U.S. Food and Drug Administration): den kommande kliniska studien uppgraderas för att kunna ligga till grund för en registreringsansökan.

2025-05-16 09:42Press release

MedVasc tar in 10 MSEK för att accelerera slutförande och FDA-förberedelser för Solutio™-enheten

MedVasc har framgångsrikt genomfört en finansieringsrunda på 10 miljoner kronor. Kapitalet kommer att användas för att stödja företagets slutliga produktutvecklingsfas samt förberedelser inför regulatoriskt godkännande i USA.

2025-05-06 08:10Press release

RECCAN AB säkrar 7 miljoner kronor för att ta deras banbrytande test för bukspottkörtelcancer närmare marknaden

RECCAN AB har säkrat 7 miljoner kronor genom en riktad nyemission, där Sandberg Development är största investerare. Kapitalet kommer att finansiera klinisk validering och verifiering av produktionsprocesser inför CE-märkning och lansering i Europa.

2025-04-14 12:05Press release

SmiLe stärker global innovation inom life science genom att stödja lanseringen av den finska OYSTER-inkubatorn

SmiLe Venture Hub bidrar till utvecklingen och lanseringen av den nya OYSTER-inkubatorn, som har skapats för att påskynda innovation inom hälsa och life science i Finland.

2025-03-31 11:40Press release

Capillon Analytics banar väg för tidig cancerdiagnostik genom håranalys 

Det nya SmiLe-bolaget Capillon Analytics utvecklar en innovativ metod för tidig upptäckt av cancer baserad på håranalys. Med hjälp av en AI-driven teknik som identifierar kemiska signaturer i hårstrån kan deras metod revolutionera cancerdiagnostiken.

2025-03-27 11:55Press release

Nya SmiLe-bolaget Strike Pharma utvecklar banbrytande precisionsmedicin

Strike Pharma är antaget till SmiLes inkubatorprogram. Bolaget har tagit fram en teknologiplattform som gör det möjligt att selektivt leverera läkemedel inneslutna i nanopartiklar till olika celler i kroppen.Med bolagets innovation kan immunceller programmeras om inne i kroppen (in vivo).

2025-02-14 08:10Press release

Zeiss blir ny labbpartner till SmiLe Venture Hub

SmiLe har ingått ett partnerskap med Zeiss, ett ledande företag inom utveckling, tillverkning och marknadsföring av optiska instrument. Zeiss har levererat tre nya mikroskop och uppgraderat ett antal befintliga mikroskop.

2025-02-12 08:10News

SmiLe välkomnar Magnhild Owman som ny People & Culture coach

SmiLe Venture Hub stärker sitt stöd till startups genom att välkomna Magnhild Owman som ny People & Culture coach. Med över 20 års erfarenhet inom rekrytering och organisationsutveckling kommer hon att stötta SmiLes bolag i frågor kring ledarskap, företagskultur och rekryteringsstrategi. 

2025-02-06 08:30Press release

Ny teknik från Emulsi Biotech kan göra biologiska läkemedel mer effektiva

Emulsi Biotech utvecklar en banbrytande plattformsteknik för administrering av orala läkemedel. Deras innovativa NanoLIPID-plattform har potential att kunna skydda läkemedelssubstanser, ge en långsam frisättning och avsevärt förbättra kroppens upptag av läkemedel.

2025-01-24 10:13Press release

SmiLe Inject Capital investerar 3 miljoner kronor i Xaga Surgical

SmiLe Inject Capital investerar 3 miljoner kronor i Xaga Surgical, ett medicinteknikbolag som utvecklar innovativa medicinska nålar för att minska risken för infektioner och förbättra cancerdiagnostik. Investeringsrundan uppgår till totalt 8 miljoner kronor.

2025-01-17 12:37News

SmiLe rekryterar Malin Sjöö för att stärka stödet till foodtech-bolag

SmiLe Venture Hub är glada att välkomna Malin Sjöö tillbaka till SmiLe när hon nu tillträder den nyinrättade rollen som Chief Innovation Officer. Malin Sjöö ska ansvara för att vidareutveckla SmiLes foodtechverksamhet samt leda coachteamets arbete.

2025-01-14 08:15Press release

Xinnate får särläkemedelsstatus från amerikanska FDA för TCP-25

Den amerikanska läkemedelsmyndigheten (FDA) har beviljat särläkemedelsstatus (Orphan Drug Designation, ODD) för Xinnates läkemedelskandidat TCP-25 för behandling av Epidermolysis Bullosa (EB), en svår genetisk sjukdom.

2025-01-10 08:15Press release

Bio-Rad blir ny labbpartner till SmiLe Venture Hub

Bio-Rad blir ny labbpartner till SmiLe Venture Hub. Genom detta partnerskap är Bio-Rads toppmoderna QX600™ AutoDG Droplet Digital PCR System nu tillgängligt för företag som använder SmiLes laboratorier i Lund.

2024-12-19 12:00Press release

ImmuneBiotech and Lund University Launch a Pioneering Clinical Study Linking Gut Health to Preeclampsia Prevention

ImmuneBiotech and Lund University Launch a Pioneering Clinical Study Linking Gut Health to Preeclampsia Prevention.

2024-12-19 12:00Press release

ImmuneBiotech och Lunds universitet inleder banbrytande klinisk studie om tarmhälsa och havandeskapsförgiftning

ImmuneBiotech inleder, i samarbete med Lunds universitet och Skånes universitetssjukhus, en klinisk studie för att undersöka om probiotika kan minska risken för havandeskapsförgiftning.

2024-12-18 08:30Press release

Dx4Life säkrar finansiering inför lansering av sitt banbrytande snabbtest för IVF-behandlingar

SmiLe-bolaget Dx4Life har genomfört en nyemission på 6,4 miljoner kronor för att förbereda lanseringen av ett unikt snabbtest som markant kommer att öka andelen lyckade IVF-behandlingar.

2024-11-11 11:01News

Greenfood och Tekinn ska förvandla grönsaksrester till näringsrik råvara

SmiLe-bolaget Tekinn har tillsammans med Greenfood, en av Nordens ledande koncerner inom hälsosam mat, fått stöd från Vinnova för att förvandla 400 ton vitkålsrester till råvara – och potentiellt rita om kartan för framtidens matsystem och dess restströmmar.

2024-11-04 08:15Press release

Aligned Bio har säkrat 19,4 miljoner kronor för att skala upp sin banbrytande nanotrådsteknik

SmiLe-bolaget Aligned Bio har framgångsrikt genomfört en finansieringsrunda och rest 19,4 miljoner kronor för att accelerera utvecklingen och uppskalningen av sin produktionsteknik för nanotrådar. Bolaget är antaget till SmiLes inkubatorprogram.

2024-10-31 13:00Press release

Ulrika Ringdahl ny VD för SmiLe Venture Hub

SmiLes vice vd Ulrika Ringdahl tillträder som ny vd för SmiLe. Hon efterträder Ebba Fåhraeus som efter tio år på posten har meddelat att hon önskar lämna rollen som vd.

2024-10-02 11:42News

AAX Biotech säkrar kapital för att främja teknikutveckling och tillväxt

SmiLe-bolaget AAX Biotech har framgångsrikt tagit in 7 MSEK i en finansieringsrunda med stöd från både nya och befintliga investerare. Kapitalet kommer att användas för att driva bolagets fortsatta tillväxt och innovationsarbete, stärka de interna resurserna och expandera projektportföljen.

2023-09-06 13:00News

SmiLe-bolaget Yazen Health tar in 37 MSEK

SmiLe-bolaget Yazen Health tar in 37 miljoner kronor för att expandera i Europa. Den digitala överviktskliniken Yazen behandlar fetma genom att kombinera viktminskningsläkemedel och livsstilsförändringar.

2021-04-29 14:25News

Innovativa healthtech-projekt kickstartar i SmiLe Bootcamp

SmiLes tioveckorsprogram för tidiga bolag och entreprenörer med innovativa idéer och produkter inom healthtech, medtech och e-Hälsa genomförs nu för sjunde gången. Projekten handlar om lösningar till exempelvis smärta, psykiatriska sjukdomar och problem efter förlossning. Målet är att göra projekten investeringsredo.

2020-07-15 09:35News

Agilents banbrytande LC/Q-TOF instrument är nu tillgängligt på SmiLe

SmiLe Incubator välkomnar Agilent, en global ledare inom laboratorieinstrument, som diamantsponsor för laboratoriet. Tack vare detta partnerskap kan SmiLe nu, via Open Lab Skåne, erbjuda sina start-up medlemmar, Medicon Village medlemmar och andra start-up bolag inom life science tillgång till toppmodern LC/Q-TOF teknologi.

2020-06-10 14:44News

Succé för VD-coachning i samarbete mellan Almi och SmiLe

Genom samarbetet mellan SmiLe och Almi har företagsledare från åtta SmiLe-bolag fått möjlighet att delta i ett VD-program i regi av Almi Företagspartner. Det är första gången Almi har gett något liknande för en VD-grupp som består av enbart life science-bolag och i sina omdömen höjer deltagarna programmet till skyarna.

2020-06-08 15:26News

Efterfrågan ökar för onlinekurser om psykisk hälsa

"Coronakrisen har fått många att uppleva en ökad mental stress och oro. Pressen på vården har även fått fler att använda digitala vårdtjänster. Nu lanserar Moodhero sin tredje kurs om att bli bättre på att hantera sin oro".

2020-05-25 15:18News

Nu har det 15:e alumnibolaget från SmiLe börsnoterats

Nu har det 15:e alumnibolaget från SmiLe noterats. Det är Bioextrax som sedan april kan handlas på Spotlight Stock Market. Bolaget utvecklar teknologiplattformar som används för att omvandla organiskt avfall till miljövänliga material som exempelvis bioplast, djurfoder och fibrer.

2020-05-18 09:04News

SmiLe stärker teamet inom marknadsföring och HR

För att ytterligare stärka SmiLe-teamet och erbjuda omfattande stöd till inkubatorbolagen kan vi nu presentera två nya team-medlemmar: Maria Sverka, Marknadschef, och Lena Axen Jergmo, People & Culture Coach.

2019-12-05 14:04Blog

Visiting EIT Health Summit in Paris

This year we are taking part in matchmaking meetings at the #EITHEALTHSUMMIT

CONTACT US

info@smileventurehub.com

SmiLe Venture Hub
Medicon Village
Scheeletorget 1
223 63 Lund
Sweden

STAY UP TO DATE

Sign up to our newsletter
Download our Press kit
Read our Privacy Policy

FOLLOW US

© 2023 Copyright SmiLe Incubator
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Accept settingsHide notification only